Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 4:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 488 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gastroesophageal Reflux Disorder Clear all
Completed Phase 3 Interventional

The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Reflux

NCT00324974
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Lansoprazole microgranules suspension, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
1 Month to 11 Months
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
9
States / cities
Tampa, Florida • Park Ridge, Illinois • Shreveport, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2010 · Synced Oct 13, 2026, 4:00 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease

NCT01045096
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
1 Year to 11 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Anaheim, California • Miami Garden, Florida • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Oct 13, 2026, 4:00 PM EDT
Completed No phase listed Observational Results available

Correlates of GERD Symptom Severity

NCT03020550
View directory record Official record
Conditions
GERD
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 13, 2026, 4:00 PM EDT
Not listed Phase 3 Interventional

Effect of Rozerem on the Perception of GERD Symptoms in Patients With Chronic Insomnia.

NCT01128582
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Chronic Insomnia
Interventions
Rozerem (ramelteon), placebo
Drug
Lead sponsor
Southern Arizona VA Health Care System
Federal
Eligibility
Up to 82 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Oct 13, 2026, 4:00 PM EDT
Enrolling by invitation No phase listed Observational

The Johns Hopkins Heartburn Center Registry

NCT03853772
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Barrett Esophagus, Laryngopharyngeal Reflux, Esophagitis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
9
States / cities
Orange, California • Baltimore, Maryland • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 13, 2026, 4:00 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Effect of Pantoprazole 40mg Daily vs Placebo on Power Spectral Analysis of the Sleep EEG of Patients With GERD.

NCT00674245
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Pantoprazole, placebo
Drug
Lead sponsor
Southern Arizona VA Health Care System
Federal
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 19, 2010 · Synced Oct 13, 2026, 4:00 PM EDT
Terminated Not applicable Interventional Results available

Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus

NCT01129778
View directory record Official record
Conditions
Barrett Esophagus, Gastroesophageal Reflux
Interventions
Zegerid (proton pump inhibitor), Bravo pH monitoring
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 13, 2026, 4:00 PM EDT
Completed Phase 3 Interventional Results available

Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD)

NCT00868296
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
pantoprazole
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
1 Day to 12 Months
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
45
States / cities
Phoenix, Arizona • Loma Linda, California • Oakland, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 4, 2010 · Synced Oct 13, 2026, 4:00 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Pumosetrag in Patients With Gastroesophageal Reflux Disease (GERD)

NCT01161602
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Pumosetrag, Placebo
Drug · Other
Lead sponsor
Edusa Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2011
U.S. locations
5
States / cities
Scottsdale, Arizona • Anaheim, California • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2011 · Synced Oct 13, 2026, 4:00 PM EDT
Recruiting No phase listed Observational

Esophageal Cancer Risk Registry

NCT00260585
View directory record Official record
Conditions
Esophageal Cancer, Gastroesophageal Reflux Disease (GERD), Esophageal Diseases, Hiatal Hernia, Esophageal Achalasia
Interventions
Survey of client health, personal habits, family history, Blood specimen for non-DNA and DNA parts, Biopsy of esophageal/stomach tissue, lymph nodes, tumor, Biopsies, oral (saliva) and/or secretions, washings or mucosal scrapings/brushing from routine clinical surveillance endoscopies
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
7,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2050
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 13, 2026, 4:00 PM EDT
Completed Not applicable Interventional Results available

Using Electrical Bioimpedance Assessments to Estimate Perioperative Total Body Water and Postoperative Fluid Need

NCT02200055
View directory record Official record
Conditions
Intestinal Cancer, Diverticulitis, Pancreatic Cancer, Gastroesophageal Reflux Disease
Interventions
Bodystat Quadscan 4000
Device
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
18 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 13, 2026, 4:00 PM EDT
Withdrawn No phase listed Observational

Transoral Incisionless Fundoplication (TIF) for Laryngopharyngeal Reflux (LPR) Patients

NCT05579587
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Laryngopharyngeal Reflux (LPR), Reflux Disease, Gastro-Esophageal, Motility Disorder
Interventions
Transoral Incisionless Fundoplication
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 13, 2026, 4:00 PM EDT
Completed Not applicable Interventional

Evaluation of Gastroesophageal Reflux in Patients on Continuous Positive Airway Pressure Ventilation for Obstructive Sleep Apnea

NCT00194376
View directory record Official record
Conditions
Gastroesophageal Reflux, Sleep Apnea
Interventions
Continuous positive airway pressure ventilation
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 13, 2026, 4:00 PM EDT
Completed Not applicable Interventional Results available

LINX Reflux Management System Clinical Study Protocol

NCT00776997
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Magnetic Sphincter Augmentation
Device
Lead sponsor
Torax Medical Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 13, 2026, 4:00 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Effect of Positional Therapy on Symptoms of Gastroesophageal Reflux Disease: A Prospective Pilot Study

NCT04500288
View directory record Official record
Conditions
Gastro Esophageal Reflux
Interventions
LEFT Device
Device
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 13, 2026, 4:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Minimally-Invasive Sponge on a String Device for Screening for Barrett's Esophagus

NCT02560623
View directory record Official record
Conditions
Barrett Esophagus
Interventions
Biopsy, Biospecimen Collection, Endoscopic Procedure, Swallowable Sponge Cell Sampling Device
Procedure · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
6
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Mankato, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 13, 2026, 4:00 PM EDT
Recruiting Phase 4 Interventional

Gastrointestinal Dysmotility on Aspiration Risk

NCT05455359
View directory record Official record
Conditions
Esophageal Motility Disorders, Gastric Motor Dysfunction, Aspiration Pneumonia, Gastro Esophageal Reflux
Interventions
Prucalopride, Famotidine
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 13, 2026, 4:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Screening for Barrett's Esophagus in Otolaryngology Patients

NCT00695227
View directory record Official record
Conditions
Extraesophageal Symptoms, Cough, Throat Clearing, Hoarseness, Difficulty Swallowing
Interventions
Screening for Barrett's Esophagus
Diagnostic Test
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 90 Years
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Oct 13, 2026, 4:00 PM EDT
Completed Not applicable Interventional

Per Oral Endoscopic Myotomy (POEM) for Esophagogastric Junction Outflow Obstruction (EGOO)

NCT01942018
View directory record Official record
Conditions
Esophagogastric Junction Outflow Obstruction
Interventions
POEM
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 13, 2026, 4:00 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia

NCT04614974
View directory record Official record
Conditions
Laryngomalacia, Gastro Esophageal Reflux
Interventions
Famotidine, Speech Language Therapy
Drug · Other
Lead sponsor
Reema Padia
Other
Eligibility
0 Months to 6 Months
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 13, 2026, 4:00 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents

NCT01642615
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Erosive Esophagitis
Interventions
Dexlansoprazole, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
12 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
32
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 13, 2026, 4:00 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Effect of High PCO2 Solution on Esophageal Acid Sensation

NCT01128608
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
24-Hr Esohpageal pH Monitoring, PCO2 Acid Perfusion and 0.1N HCI Perfusion
Procedure
Lead sponsor
Southern Arizona VA Health Care System
Federal
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 21, 2010 · Synced Oct 13, 2026, 4:00 PM EDT
Active, not recruiting Not applicable Interventional

Reflux Band in Laryngopharyngeal Reflux

NCT04827355
View directory record Official record
Conditions
Laryngopharyngeal Reflux
Interventions
External Upper Esophageal Sphincter (UES) Compression Device, Sham Device
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 13, 2026, 4:00 PM EDT
Completed Not applicable Interventional

The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis

NCT01733810
View directory record Official record
Conditions
Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease
Interventions
Cessation of Acid Suppressing Medications
Other
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 13, 2026, 4:00 PM EDT